Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment

Fig. 2

In vitro synergism analysis for two-drug combinations of BKM120, MEK162 and SN38. (a) Experimental survival data (SRB assay; left) and synergism (right) matrices for HCT116 cells incubated with the indicated two-drug combinations at the indicated doses. In the blue matrices, values indicate the percentage of surviving cells. In the synergism matrices, the green to red scale is used to indicate antagonist combinations (green) and synergistic combinations (red). The black cells show additive combinations. (b) Combination indices for all the CRC cell lines incubated with two-drug combinations of BKM120, MEK162 or SN38. (c) Synergism matrix for the BKM120-MEK162 combinations focused on the synergism area. Table 1 shows the features of each cell line

Back to article page